July 27, 2021
A pairing of Eisai’s multikinase inhibitor Lenvima (lenvatinib) and US Merck’s PD-1 inhibitor Keytruda (pembrolizumab) has won regular US approval for patients with certain types of endometrial carcinoma, a conversion from the combo’s accelerated nod granted in 2019. The full...read more